Obstetrics & Gynaecology | Home

Malaysia
Search
Sign In

Obstetrics & Gynaecology Search

Obstetrics & Gynaecology

Obstetrics & Gynaecology

Home News Diseases Conferences Special Reports Multimedia

Relugolix combo therapy preserves bone mass in women with heavy period

Pearl Toh, Yesterday

Combining the oral GnRH* receptor antagonist relugolix together with oestradiol and the progestin norethindrone helps protect against bone loss induced by oestrogen deprivation associated with the use of GnRH receptor antagonist monotherapy for treating heavy menstrual bleeding, according to the LIBERTY studies released during the ACOG 2020 Meeting.

Study reveals inverse association between breast cancer, arthritis

Audrey Abella, Yesterday

Women with rheumatoid arthritis (RA) have a reduced risk of breast cancer; similarly, women with breast cancer have a reduced risk of RA, reveals a Swedish study. Moreover, adjuvant antihormonal therapy for breast cancer prevention does not appear to increase the risk of RA.

Original New Drug Application Approvals by US FDA (16 - 31 May 2020)

2 days ago

New drug applications approved by US FDA as of 16 - 31 May 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Regular yoga of help for PCOS?

Pearl Toh, 3 days ago

Women with PCOS* who practised mindful yoga thrice weekly had significantly lower free testosterone levels, a main criterion for the diagnosis of PCOS, a small study shows, suggesting yoga as a potential non-pharmacologic complementary treatment option for women with PCOS.

Expert consensus: Patient profile should guide antihistamine choice in primary care setting

10 Dec 2019

Oral H₁-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.

The Evolving Role of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 in Women’s Urogenital Health

12 Jun 2019

Urogenital infections remain a major reason for women to visit their family physician and their subsequent referral to obstetrics and gynaecology or urology specialists. The association between abnormal vaginal microbiota and an increased risk of contracting sexually transmitted diseases (STDs), as well as an increased rate of preterm labour, indicates the need to better understand and manage urogenital health in women. Probiotics are “live microorganisms which, when administered in adequate amounts, confer a health benefit on the host”. As such, there is a sound rationale for using probiotics to maintain female vaginal and bladder health.

Relugolix combo therapy preserves bone mass in women with heavy period

Pearl Toh, 02 Jun 2020

Subgroup findings boost elagolix benefit in uterine fibroid-induced menstrual bleeding

Audrey Abella, 29 May 2020

The addition of the oral GnRH* antagonist elagolix to hormonal add-back therapy (E2/NETA**) reduces menstrual blood loss (MBL) in women with heavy menstrual bleeding (HMB) associated with uterine fibroids (UF) and comorbid adenomyosis, with the extension phase showing benefits beyond 6 months, according to data presented at ACOG 2020.

Vaginal cleansing prophylaxis reduces SSIs after Caesarean delivery

Roshini Claire Anthony, 27 May 2020

The use of a vaginal cleansing intervention prior to Caesarean delivery reduced the incidence of surgical site infections (SSIs), according to a study presented at ACOG 2020. However, the addition of intravenous (IV) azithromycin prophylaxis had no added impact on SSI rates.

GU symptoms down, sexual satisfaction up with new vaginal contraceptive gel

Audrey Abella, 26 May 2020

A novel, investigational vaginal pH regulator (VPR) – a nonhormonal, water-based, petroleum-free contraceptive vaginal gel – improved genitourinary (GU) side effects and sexual satisfaction in women who are at risk of pregnancy but are not aiming to conceive, interim findings from the phase III AMPOWER* trial show.

Contraception with LNG-IUD still effective up to 6 years

Pearl Toh, 21 May 2020

A levonorgestrel (LNG)-releasing intrauterine device (IUD) maintains high contraceptive efficacy up to 6 years, which is beyond the 5-year period it is currently approved for, according to data from the Mirena Extension Trial (MET) released during the ACOG 2020 Meeting.

Olaparib-bevacizumab PFS benefit in ovarian cancer greatest following upfront surgery

Roshini Claire Anthony, 20 May 2020

The combination of olaparib and bevacizumab as maintenance therapy for advanced ovarian cancer appears to confer the greatest progression-free survival (PFS) benefit in women without residual macroscopic disease following upfront cytoreductive surgery, according to an analysis of the phase III PAOLA-1* trial.

Subgroup findings boost benefit of niraparib in newly-diagnosed ovarian cancer

Audrey Abella, 14 May 2020

The PARP* inhibitor niraparib improves progression-free survival (PFS) and is well-tolerated in women with newly diagnosed advanced ovarian cancer (OCa) after a response to first-line (1L) platinum-based chemotherapy (CT), subgroup results of the phase III PRIMA/ENGOT-OV26/GOG-3012 trial have shown.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!